Updated on 15 November 2013
Having resolved the NASDAQ compliance issue, Biostar can now continue focusing on maximizing shareholder value and strengthen its business
Singapore: Biostar Pharmaceuticals, a China-based manufacturer and marketer of pharmaceutical and health supplement products for a variety of diseases and conditions, has regained compliance Rule 5550(a)(2), which requires a minimum bid price of $1 for continued listing on the NASDAQ Stock Market.
Mr Ronghua Wang, chairman, Biostar, while commenting on the announcement, stated that, "We strongly believe that regaining compliance with NASDAQ's continued listing requirements is an important achievement for the company. Having resolved this issue, we can continue focusing on maximizing shareholder value and strengthening the company's business going forward."